Published in JAMA on June 07, 2006
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | NCT00480935
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer (2007) 4.22
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 4.07
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer (2014) 2.26
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J (2007) 1.72
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer (2008) 1.69
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67
Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol (2008) 1.60
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59
Targeted therapy in renal cell carcinoma. World J Urol (2008) 1.56
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res (2015) 1.53
Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy (2008) 1.49
Roles for VEGF in the adult. Microvasc Res (2007) 1.48
Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol (2011) 1.46
Sunitinib in advanced renal cell carcinoma: new treatment option? Curr Oncol Rep (2007) 1.39
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 1.39
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. J Oncol (2009) 1.38
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs (2010) 1.33
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer (2009) 1.33
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist (2011) 1.30
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat (2009) 1.25
Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest (2010) 1.25
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer (2010) 1.25
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol (2011) 1.24
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer (2013) 1.24
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci U S A (2008) 1.20
A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. Elife (2015) 1.20
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist (2010) 1.20
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs (2012) 1.13
What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol (2008) 1.13
A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets (2012) 1.12
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther (2010) 1.10
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther (2009) 1.07
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag (2007) 1.07
Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther (2010) 1.05
Update on systemic therapies of metastatic renal cell carcinoma. World J Urol (2010) 1.05
Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer (2008) 1.05
Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol (2013) 1.05
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer (2015) 1.05
Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol (2010) 1.04
Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer (2008) 1.04
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer (2009) 1.04
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int (2009) 1.03
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
The clinical implications of the genetics of renal cell carcinoma. Urol Oncol (2009) 1.03
Pazopanib. Nat Rev Drug Discov (2010) 1.02
Targeted therapies for non-clear renal cell carcinoma. Target Oncol (2010) 1.02
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol (2013) 1.01
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol (2013) 1.01
Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer (2013) 1.00
Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer (2006) 0.99
Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther (2008) 0.99
[Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options]. Pathologe (2008) 0.98
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res (2015) 0.97
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One (2013) 0.97
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist (2011) 0.97
The role of PDGF in radiation oncology. Radiat Oncol (2007) 0.97
The von Hippel-Lindau gene: turning discovery into therapy. Cancer (2008) 0.97
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol (2008) 0.96
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis (2014) 0.95
Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol (2011) 0.94
Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol (2009) 0.94
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer (2009) 0.94
Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget (2015) 0.93
Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2012) 0.93
Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer (2014) 0.93
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol (2010) 0.93
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. J Cancer Res Clin Oncol (2008) 0.93
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer (2008) 0.92
Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent) (2007) 0.92
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med (2010) 0.92
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. Eur Urol (2015) 0.92
Anti-angiogenesis approach to genitourinary cancer treatment. Update Cancer Ther (2009) 0.92
Merkel cell carcinoma: the past, the present, and the future. J Skin Cancer (2013) 0.92
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy (2011) 0.91
Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS One (2013) 0.91
Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection. BJU Int (2008) 0.91
Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol (2007) 0.90
Antiangiogenic therapy in renal cell carcinoma: from concept to reality. Nat Clin Pract Urol (2007) 0.90
Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer. J Am Coll Cardiol (2012) 0.89
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology (2015) 0.89
Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report. World J Urol (2012) 0.89
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs (2012) 0.89
Nephrotoxicity of recent anti-cancer agents. Clin Kidney J (2013) 0.89
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer (2015) 0.89
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 4.07
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology (2009) 3.30
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res (2011) 3.25
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol (2008) 3.16
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol (2011) 3.05
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.69
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol (2012) 2.56
Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Therapy-induced senescence in cancer. J Natl Cancer Inst (2010) 2.45
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol (2010) 2.44
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40